TG Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
368.52 | 61.47 | 499.46% | 106.11 | +247.29% |
| P/S |
|
19.99 | 33.58 | -40.48% |
|
|
| P/BV |
|
29.1 | 4.79 | 507.12% |
|
|
| P/FCF |
|
-49.66 | 42.53 | -216.76% |
|
|
| Ev/Ebitda |
|
179.61 | -17.26 | -1140.56% |
|
|
| Ev/S |
|
20.06 | 22.49 | -10.78% |
|
|
| Ev/FCF |
|
-149.23 | 67.63 | -320.66% |
|
|
| E/P |
|
0.0081 | 0.0182 | -55.49% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
4/10
|
11.17 | -14.2 | -178.64% | -2365.11 | -100.47% |
| ROE |
|
7.9 | 9.78 | -19.29% |
|
|
| ROA |
|
3.84 | 0.33 | 1064.92% |
|
|
| ROIC |
|
-86.89 | 7.63 | -1238.14% |
|
|
| ROS |
|
5.42 | -26.41 | -120.52% |
|
|
| ROCE |
|
16 | 14.76 | 8.42% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
2/10
|
4.25 | -3.68 | -215.39% | 2.62 | +62.25% |
| Nеt Debt/Ebitda |
|
0.6844 | -4.07 | -116.83% |
|
|
| Debt/Ratio |
|
0.3362 | 0.199 | 68.92% |
|
|
| Debt/Equity |
|
360.9 | 1.67 | 21574.29% |
|
|
| Debt/Net Income |
|
8.74 | 10.34 | -15.46% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5399 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.235 | -100% |
|
|
| Average dividend growth |
|
0 | 1.41 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.486 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.64 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5399 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
153625 | 76.2 | 201507.61% | ||
| Growth impulse Ebitda in 5 years |
|
-109.56 | 44.75 | -344.83% | ||
| Growth impulse Net Income in 5 years |
|
-104.54 | -15.36 | 580.6% | ||
| Growth impulse FCF in 5 years |
|
-85.38 | -31.68 | 169.51% | ||
| Growth impulse EPS in 5 years |
|
-103.53 | -61.82 | 67.47% |
IP Score
2.33/10
